#brain #synaptic #plasticity #NMDR, #AptinyX #Allergan #rewire #treatment
Aptinyx Inc. (NASDAQ:APTX) now has a Strong Buy rating with an 20+ price target long term, we note that the company has opened a path to NMDAR modulation that can restore synaptic plasticity and rewire the brain.
APTX broke out on 6 May and confirmed on 1 July and is moving towards it 52 wk high at 5.28 Vs its 19 March low at 1.60.
The stock has Strong Support at 4.14, and the resistance is Nil.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.
The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson’s disease cognitive impairment.
The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in Y 2015 and is HQ’d in Evanston, Illinois.
Have a healthy day, Keep the Faith!
Latest posts by Paul Ebeling (see all)
- Globalist Ideology Undermines President Trump’s Vision of America - October 31, 2020
- Travel: “Get the Jet” - October 31, 2020
- These Foods Can Cause Food Poisoning - October 31, 2020